[Corticoid-induced osteoporosis. Pathogenesis, diagnosis and treatment].

[Osteoporosis induced by corticoids]. Medicina (B Aires) (1993) 0.75

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 9.71

Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin (2003) 1.62

Mechanical validation of a tomographic (pQCT) index for noninvasive estimation of rat femur bending strength. Bone (1996) 1.42

Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron (1996) 1.42

Gender-related differences in the relationship between densitometric values of whole-body bone mineral content and lean body mass in humans between 2 and 87 years of age. Bone (1998) 1.14

Interrelationships between densitometric, geometric, and mechanical properties of rat femora: inferences concerning mechanical regulation of bone modeling. J Bone Miner Res (1993) 1.12

The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int (2008) 1.06

The vacuum cleft sign: an uncommon radiological sign. Osteoporos Int (2005) 1.03

Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int (2006) 1.01

Vitamin D and bone mineral density in ambulatory women living in Buenos Aires, Argentina. Osteoporos Int (2001) 0.95

Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol (1992) 0.94

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int (2009) 0.94

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int (2012) 0.90

Dexamethasone effects on mechanical, geometric and densitometric properties of rat femur diaphyses as described by peripheral quantitative computerized tomography and bending tests. Bone (1995) 0.88

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int (2011) 0.86

Determination of femur structural properties by geometric and material variables as a function of body weight in rats. Evidence of a sexual dimorphism. Bone (1993) 0.84

Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients. Osteoporos Int (2012) 0.84

Effects of large doses of olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture, and mechanical properties of rat femurs. Bone (1995) 0.83

[Association between Paget's disease and primary hyperparathyroidism]. Medicina (B Aires) (1997) 0.82

Evaluation of cortical bone by peripheral quantitative computed tomography in renal transplant recipients. Transplant Proc (2005) 0.82

Calcium bioavailability and parathyroid hormone acute changes after oral intake of dairy and nondairy products in healthy volunteers. Osteoporos Int (1999) 0.82

Densitometric and tomographic analyses of musculoskeletal interactions in humans. J Musculoskelet Neuronal Interact (2000) 0.81

[Metabolic evaluation at the time of the first renal lithiasis episode]. Medicina (B Aires) (1995) 0.80

Interrelationships between geometric and mechanical properties of long bones from three rodent species with very different biomass: phylogenetic implications. J Bone Miner Res (1992) 0.80

Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner (1993) 0.79

Lumbar spine bone density in Argentine children. Calcif Tissue Int (1996) 0.79

[Metabolic changes in 2612 patients with nephrolithiasis]. Medicina (B Aires) (1999) 0.77

[Tolerability of oral bisphosponates in patients with osteoporosis and other osteopathies]. Medicina (B Aires) (1997) 0.76

Denosumab: an update. Drugs Today (Barc) (2011) 0.76

[Vitamin D status in women living in Buenos Aires]. Medicina (B Aires) (1999) 0.75

[Various unsolved questions on osteoporosis]. Medicina (B Aires) (1994) 0.75

[Current treatment of bronchial asthma]. Medicina (B Aires) (1993) 0.75

Monophasic dose-response curves of betamethasone on geometric and mechanical properties of femur diaphyses in growing rats. Bone (1995) 0.75

Effect of antiresorptive therapy on day-to-day variation of urinary free deoxypyridinoline excretion. Clin Chem (1998) 0.75

[Relationship between weight, body composition and bone mass in peritoneal dialysis]. Nefrologia (2005) 0.75

[Relationship between renal function and bone mineral density in postmenopausal women that undergo bone mass evaluation]. Nefrologia (2006) 0.75

[Primary hyperparathyroidism and renal lithiasis. Effect of delay in diagnosis on the morbidity]. Arch Esp Urol (1985) 0.75

[Experimental effects of olpadronate and pamidronate on bone mass]. Medicina (B Aires) (1997) 0.75

Intravenous olpadronate restores ovariectomy-affected bone strength. A mechanical, densitometric and tomographic (pQCT) study. Bone (1995) 0.75

[Postmenopause, plasma lipoproteins, and hormone replacement therapy]. Medicina (B Aires) (1993) 0.75

Glycosaminoglycans in urolithiasis. Nephron (1992) 0.75

Long-term low-dose glucocorticoid therapy in hyperandrogenized women: utility and effects on bone mineral content and hypothalamic-pituitary-adrenocortical function. Horm Res (1991) 0.75

[Renal lithiasis. Up-date and experience in its metabolic study and medico-surgical treatment]. Arch Esp Urol (1982) 0.75

[Alcoholic osteopathy]. Medicina (B Aires) (1994) 0.75

[Bone mineral content and treatment with deferoxamine in patients under chronic hemodialysis]. Medicina (B Aires) (1992) 0.75

[Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia]. Medicina (B Aires) (1995) 0.75

[Estimation of the prevalence of low turn over renal osteodystrophy using biological markers in a peritoneal dialysis population]. Nefrologia (2001) 0.75

[Bioavailability of fluorine administered as sodium monofluorophosphate combined with calcium salts]. Medicina (B Aires) (1990) 0.75

Lean body mass estimation by densitometry and creatinine kinetics in chronic peritoneal dialysis patients. Perit Dial Int (2000) 0.75

Osteoporosis following heart transplantation. Transplant Proc (1996) 0.75

[Whole PTH and 1-84/84 PTH ratio for the non invasive determination of low bone turnover in renal osteodysthrophy]. Nefrologia (2003) 0.75

[Serum levels of 25-hydroxyvitamin D and bone mineral density of femur neck of postmenopause women]. Medicina (B Aires) (1993) 0.75

[Urine saturation with calcium oxalate in urolithiasis]. Medicina (B Aires) (1988) 0.75